Emerging Company Profile: Orum Therapeutics is aiming to develop a first-in-class therapeutic antibody for cancer and other intractable diseases, using its unique cell-penetrating antibody platform. Following a successful Series A financing, the young South Korean biotech’s next big milestone is to enter clinical trials by 2019 with its first program in oncology, targeting activated RAS protein.
Formerly the head of research, Asia Pacific R&D, at Sanofi, Sung Joo Lee, CEO and co-founder of Orum Therapeutics Inc., has long been interested in innovative novel drug research and has been searching for platforms that can address undruggable targets.
He found an interesting prospect in research at South Korea’s Ajou University and proposed Professor Yong Sung Kim - leading...